X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1873) 1873
Publication (431) 431
Book Review (15) 15
Book Chapter (14) 14
Dissertation (3) 3
Conference Proceeding (2) 2
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1066) 1066
humans (1037) 1037
animals (885) 885
male (794) 794
soluble epoxide hydrolase (632) 632
female (527) 527
epoxyeicosatrienoic acids (428) 428
epoxide hydrolases - metabolism (418) 418
enzymes (388) 388
epoxide hydrolases - genetics (383) 383
mice (368) 368
epoxide hydrolase (346) 346
rats (344) 344
pharmacology & pharmacy (322) 322
epoxide hydrolases - antagonists & inhibitors (301) 301
middle aged (301) 301
microsomal epoxide hydrolase (295) 295
biochemistry & molecular biology (279) 279
adult (278) 278
article (274) 274
hypertension (260) 260
arachidonic-acid (252) 252
inflammation (239) 239
hydrolases (234) 234
metabolites (218) 218
metabolism (215) 215
cardiovascular system (211) 211
genotype (207) 207
cytochrome p-450 enzyme system - metabolism (206) 206
blood-pressure (205) 205
toxicology (205) 205
risk factors (190) 190
expression (189) 189
physiological aspects (180) 180
polymorphism, genetic (178) 178
aged (175) 175
cell biology (172) 172
genetic aspects (171) 171
research (166) 166
lipids (160) 160
arachidonic acid (158) 158
cytochrome p-450 (158) 158
analysis (153) 153
inhibition (150) 150
8,11,14-eicosatrienoic acid - analogs & derivatives (147) 147
cytochrome p450 (147) 147
physiology (144) 144
genetic predisposition to disease (140) 140
mice, inbred c57bl (139) 139
enzyme inhibitors - pharmacology (138) 138
peripheral vascular disease (131) 131
polymorphism (130) 130
oncology (129) 129
oxidative stress (127) 127
risk (127) 127
disease models, animal (122) 122
rodents (122) 122
cancer (121) 121
case-control studies (121) 121
glutathione transferase - genetics (119) 119
health aspects (115) 115
multidisciplinary sciences (115) 115
rats, sprague-dawley (114) 114
genetic polymorphisms (113) 113
susceptibility (110) 110
polymorphism, single nucleotide (105) 105
genetics & heredity (104) 104
mice, knockout (104) 104
dose-response relationship, drug (103) 103
cytochrome p-450 enzyme system - genetics (102) 102
medicine (99) 99
gene expression (98) 98
association (96) 96
research article (95) 95
8,11,14-eicosatrienoic acid - metabolism (93) 93
cardiac & cardiovascular systems (92) 92
glutathione-s-transferase (91) 91
solubility (91) 91
genes (90) 90
arachidonic acid - metabolism (89) 89
in-vitro (88) 88
eicosanoids - metabolism (87) 87
proteins (87) 87
fatty acids (84) 84
unsaturated fatty acids (84) 84
liver (83) 83
smoking (83) 83
eicosanoids (80) 80
staphylococcal enterotoxin h (80) 80
polymorphisms (79) 79
activation (78) 78
respiratory system (78) 78
epoxyeicosatrienoic acid (77) 77
neurosciences (76) 76
genetics (75) 75
cells, cultured (74) 74
blood pressure (72) 72
therapeutic target (72) 72
atherosclerosis (70) 70
disease (70) 70
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell and Tissue Research, ISSN 0302-766X, 2/2016, Volume 363, Issue 2, pp. 399 - 409
Epoxyeicosatrienoic acids (EETs), the metabolites of arachidonic acid derived from the cytochrome P450 (CYP450) epoxygenases, are mainly metabolized by soluble... 
Human Genetics | Biomedicine | Pulmonary fibrosis | Mouse | Proteomics | Soluble epoxide hydrolase inhibitor | Epoxyeicosatrienoic acids | Molecular Medicine | Proliferation | CYP2J2 | APOPTOSIS | MECHANISMS | NEPHROPATHY | CELL BIOLOGY | INFLAMMATION | IN-VIVO | EETS | NIH 3T3 Cells | Eicosanoids - chemistry | Male | Pulmonary Fibrosis - blood | Weight Loss - drug effects | Interleukin-1beta - blood | Bleomycin | Piperidines - pharmacology | Interleukin-6 - blood | Cell Death - drug effects | Transforming Growth Factor beta1 - blood | Fibroblasts - metabolism | Lung - pathology | Mice, Inbred C57BL | Solubility | Phenylurea Compounds - therapeutic use | Pulmonary Fibrosis - pathology | Eicosanoids - blood | Fibroblasts - pathology | Collagen - metabolism | Animals | Cell Differentiation - drug effects | Piperidines - therapeutic use | Fibroblasts - drug effects | Lung - drug effects | Pulmonary Fibrosis - chemically induced | Cell Proliferation - drug effects | Mice | Phenylurea Compounds - pharmacology | S Phase - drug effects | Epoxide Hydrolases - metabolism | Pulmonary Fibrosis - drug therapy | Epoxide Hydrolases - antagonists & inhibitors | Enzymes | Urea | Unsaturated fatty acids | RNA | Collagen | Analysis | Cytochrome P-450 | Hydrolases | Bone morphogenetic proteins | Transforming growth factors | Muscle proteins | Cell growth | Cytokines | Gene expression | soluble epoxide hydrolase inhibitor | mouse | proliferation | epoxyeicosatrienoic acids | pulmonary fibrosis
Journal Article
Annual Review of Pharmacology and Toxicology, ISSN 0362-1642, 01/2013, Volume 53, Issue 1, pp. 37 - 58
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 12/2013, Volume 305, Issue 11, pp. H1605 - H1613
Soluble epoxide hydrolase (sEH) diminishes vasodilatory and neuroprotective effects of epoxyeicosatrienoic acids by hydrolyzing them to inactive dihydroxy... 
Ischemic stroke | Arachidonic acid | Cerebral blood flow | Middle cerebral artery occlusion | Cytochrome P-450 | arachidonic acid | TARGET | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | cytochrome P-450 | ARACHIDONIC-ACID | HYPOXIA | FREE FATTY-ACIDS | cerebral blood flow | PERIPHERAL VASCULAR DISEASE | ELECTROCONVULSIVE SHOCK | PERFUSION | CEREBRAL-ISCHEMIA | EPOXYEICOSATRIENOIC ACIDS | ischemic stroke | middle cerebral artery occlusion | BRAIN | Infarction, Middle Cerebral Artery - physiopathology | Neurons - pathology | Brain - enzymology | Motor Activity - drug effects | Male | Recovery of Function | Dose-Response Relationship, Drug | Brain - blood supply | Neuroprotective Agents - pharmacology | Time Factors | Urea - analogs & derivatives | Behavior, Animal - drug effects | Infarction, Middle Cerebral Artery - drug therapy | Cell Death - drug effects | Neurons - drug effects | Disease Models, Animal | Cerebrovascular Circulation - drug effects | Cells, Cultured | Enzyme Inhibitors - pharmacology | Rats | Infarction, Middle Cerebral Artery - pathology | Rats, Sprague-Dawley | Brain - drug effects | Hydroxyeicosatetraenoic Acids - metabolism | Animals | Neurons - enzymology | Benzoates - pharmacology | Brain - pathology | Epoxide Hydrolases - metabolism | Infarction, Middle Cerebral Artery - enzymology | Epoxide Hydrolases - antagonists & inhibitors | Urea - pharmacology | Stroke (Disease) | Benzoic acid | Physiological aspects | Enzymes | Hydrolases | Health aspects | Vascular Biology and Microcirculation
Journal Article
Chest, ISSN 0012-3692, 2016, Volume 151, Issue 3, pp. 555 - 563
Background Smoking and COPD are risk factors for cardiovascular disease, and the pathogenesis may involve endothelial dysfunction. We tested the hypothesis... 
Pulmonary/Respiratory | clinical trial | endothelial function | soluble epoxide hydrolase inhibitor | smokers | COPD | EETs | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | EPOXYGENASE | OBSTRUCTIVE PULMONARY-DISEASE | CIGARETTE-SMOKING | HYPERPOLARIZING FACTOR | CORONARY ATHEROSCLEROSIS | RESPIRATORY SYSTEM | PLASMINOGEN ACTIVATOR RELEASE | CARDIOVASCULAR-DISEASE | EPOXYEICOSATRIENOIC ACIDS | CRITICAL CARE MEDICINE | Fluconazole - pharmacology | Humans | Middle Aged | Endothelium, Vascular - drug effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | 8,11,14-Eicosatrienoic Acid - metabolism | Case-Control Studies | Blood Vessels - physiopathology | Overweight - metabolism | 8,11,14-Eicosatrienoic Acid - analogs & derivatives | Cyclohexylamines - pharmacology | Smoking - physiopathology | Forearm - blood supply | Adult | Pulmonary Disease, Chronic Obstructive - metabolism | Bradykinin - pharmacology | Triazines - pharmacology | Vasodilator Agents - pharmacology | Endothelium, Vascular - physiopathology | Overweight - physiopathology | Smoking - metabolism | Endothelium, Vascular - metabolism | Blood Vessels - drug effects | Aged | Vasodilation - drug effects | In Vitro Techniques | Epoxide Hydrolases - antagonists & inhibitors | Plethysmography | Enzymes | Lung diseases, Obstructive | Care and treatment | Smokers | Research | Risk factors | Blood circulation disorders | Analysis | Epoxy compounds | Hydrolases | Diagnosis | Health aspects | Smoking | EET, epoxyeicosatrienoic acid | SNP, sodium nitroprusside | Original Research | LNAME, L-nitroarginine methyl ester | EDHF, endothelium-derived hyperpolarizing factor | NFκB, nuclear factor kappa light-chain enhancer of activated B cells | LNMMA, NG-monomethyl-L-arginine | tPA, tissue plasminogen activator | DHET, dihydroxyepoxyeicosatrienoic acid | NO, nitric oxide | sEH, soluble epoxide hydrolase | PAI-1, plasminogen activator inhibitor type 1 | CYP, cytochrome P450 | EC50, half maximal effective concentration
Journal Article
The FEBS Journal, ISSN 1742-464X, 07/2017, Volume 284, Issue 13, pp. 1970 - 1986
Podocytes play an important role in maintaining glomerular function, and podocyte injury is a significant component in the pathogenesis of proteinuria. Soluble... 
knockout mice | soluble epoxide hydrolase | proteinuria | podocyte | BIOCHEMISTRY & MOLECULAR BIOLOGY | FACTOR-KAPPA-B | DIABETIC-NEPHROPATHY | ENDOPLASMIC-RETICULUM STRESS | LOWERS BLOOD-PRESSURE | NEPHROTIC-SYNDROME | URINE PROTEINS | MESANGIAL CELLS | PHARMACOLOGICAL INHIBITION | ACUTE-PANCREATITIS | RENAL TUBULAR DISORDERS | Kidney - pathology | Blood Urea Nitrogen | Podocytes - enzymology | Immunoblotting | Acute Kidney Injury - genetics | Kidney - metabolism | Piperidines - pharmacology | Cytokines - genetics | Cytokines - blood | Epoxide Hydrolases - deficiency | Kidney - drug effects | Cytokines - metabolism | Mice, Inbred C57BL | Cells, Cultured | Solubility | Mice, Transgenic | Signal Transduction - genetics | Proteinuria - genetics | Acute Kidney Injury - enzymology | Reverse Transcriptase Polymerase Chain Reaction | Epoxide Hydrolases - genetics | Mice, Knockout | Gene Expression Regulation - drug effects | Proteinuria - enzymology | Animals | Lipopolysaccharides - pharmacology | Phenylurea Compounds - pharmacology | Epoxide Hydrolases - antagonists & inhibitors | Microscopy, Fluorescence | Enzymes | Hydrolases | Mitogens | Renal function | Transcription | Pathogenesis | Epoxide hydrolase | Lipopolysaccharides | Interleukin 6 | Rodents | Interleukin 1 | Attenuation | Inhibition | Injuries | Kidneys | Cytokines | MAP kinase | Pharmacology | Inflammation | Nitrogen | Urea | Inhibitors | Tumor necrosis factor | Mice | In vivo methods and tests | Staphylococcal enterotoxin H | Endoplasmic reticulum | Proteinuria
Journal Article